The Peptide Craze: Where Science, Law, and the FDA Collide
Dr. Alex Tatem walks through the tangled intersection of peptide science, legal status, and FDA regulation in a way that actually makes sense of a confusing space. If you have tried to buy peptides, you have probably noticed that the rules seem to change constantly, that some compounds are available one month and restricted the next, and that the language around legality is deliberately vague. This video clears up why.
The peptide market grew from a niche biohacking interest to a mainstream health trend faster than regulators could respond. Compounds that were quietly used by a few thousand people in 2019 are now being purchased by hundreds of thousands. That explosive growth attracted both legitimate clinical interest and the kind of unregulated commercial activity that gets the FDA is attention.
The Legal Framework: What Peptides Actually Are Under the Law
Most therapeutic peptides exist in a regulatory gray zone. They are not approved drugs, meaning they have not gone through the FDA approval process (Phase 1 through Phase 3 clinical trials, followed by a New Drug Application). But they are also not dietary supplements, because injectable compounds do not qualify for supplement classification under the Dietary Supplement Health and Education Act (DSHEA) of 1994.
The way most people access peptides is through compounding pharmacies. These pharmacies are regulated under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, which allows them to prepare customized medications that are not commercially available. For years, compounding pharmacies produced peptides like BPC-157, TB-500, and various growth hormone secretagogues under this framework.
The FDA has been tightening this pathway. In 2023 and 2024, the agency placed several peptides on its list of substances that cannot be compounded, effectively removing them from legal compounding pharmacy production. The stated rationale varies. For some peptides, the FDA cited lack of safety data. For others, it cited the availability of FDA-approved alternatives or manufacturing quality concerns.
Dr. Tatem is frank about the politics involved. Some of the FDA is actions align clearly with public health protection. Others appear influenced by pharmaceutical industry lobbying, where compounded peptides compete directly with expensive patented medications. The GLP-1 space is a prime example: compounded semaglutide was a fraction of the cost of brand-name Ozempic and Wegovy, and the FDA moved to restrict it as brand supply shortages eased.
What You Can and Cannot Get Right Now
The regulatory space shifts frequently, but as of early 2026, here is the general picture. Some peptides remain available through licensed compounding pharmacies with a valid prescription. Others have been placed on the FDA is restricted list and are no longer legally available through compounding. And some exist in a gray area where enforcement is inconsistent.
BPC-157 is one of the peptides that has faced regulatory action. The FDA placed it on the list of substances that cannot be used in compounding in late 2024, citing lack of adequate safety data for human use. This was controversial because BPC-157 had been used by thousands of people through compounding pharmacies for years without significant adverse event reports. The restriction drove interest in oral BPC-157 supplements, which occupy a different regulatory space since they are not injectable.
Growth hormone secretagogues like CJC-1295 and Ipamorelin have also faced restrictions, though the specific status varies by compound and by the compounding pharmacy is classification (503A vs 503B).
GLP-1 receptor agonists went through a particularly dramatic regulatory cycle. During the severe shortages of Ozempic and Wegovy in 2023 and 2024, the FDA allowed compounding pharmacies to produce semaglutide. As brand-name supply improved, the FDA moved to restrict compounded versions, arguing they were no longer needed. This whipsawed patients who had started on compounded semaglutide at affordable prices and suddenly faced the choice of switching to brand-name at much higher cost or stopping treatment.
The Quality Problem That Drives FDA Concern
A legitimate part of the FDA is case against compounded peptides involves quality control. Unlike FDA-approved drugs, which must be manufactured in facilities that pass rigorous Good Manufacturing Practice (GMP) inspections, compounding pharmacies operate under less stringent requirements. The quality of compounded peptides varies significantly between pharmacies.
Testing by independent labs has found compounded peptides with lower potency than labeled, contamination with bacterial endotoxins, and in some cases, the wrong peptide entirely. These are not theoretical concerns. They are documented quality failures that put patients at risk.
Dr. Tatem recommends that anyone using compounded peptides request a certificate of analysis from the pharmacy showing third-party testing results for identity, potency, purity, and sterility. Reputable compounding pharmacies provide these willingly. Pharmacies that refuse or cannot provide them should be avoided.
The 503B outsourcing facility pathway provides a higher quality tier within compounding. These facilities manufacture in bulk under GMP-like conditions and are subject to FDA inspection. Peptides from 503B facilities are generally more trustworthy than those from smaller 503A pharmacies, though they are also more expensive.
Research Peptides: The Other Market
Outside of compounding pharmacies, peptides are sold by research chemical suppliers labeled "for research purposes only" and "not for human consumption." This market exists in a legal gray area where the compounds are technically legal to sell for laboratory research but illegal to sell for human use.
In practice, many people purchase research-grade peptides and use them for self-administration. Dr. Tatem does not endorse this practice but acknowledges it exists widely. The risks are higher than with compounding pharmacy products because research suppliers are not subject to pharmaceutical manufacturing standards, and quality testing is inconsistent.
If someone chooses to go this route despite the risks, third-party testing through services like Janoshik or similar analytical labs provides some degree of quality verification. But the legal, quality, and safety risks remain elevated compared to working with a licensed compounding pharmacy and a prescribing physician.
International Access and Medical Tourism
As US access to certain peptides tightens, some people are looking internationally. Countries like Mexico, Thailand, and several European nations have different regulatory frameworks for peptides, and medical tourism for peptide therapy is a growing trend. Some international clinics offer peptide protocols that are not available through US compounding pharmacies.
Dr. Tatem advises caution with this approach. Quality assurance varies enormously between international providers. Some clinics maintain excellent standards. Others operate with minimal oversight and questionable product sourcing. The absence of US regulatory protection means you are relying entirely on the clinic is own quality controls.
If you pursue international peptide therapy, research the clinic thoroughly. Look for clinics staffed by licensed physicians, ideally with credentials recognizable in your home country. Ask about their peptide sourcing and whether they use products from GMP-certified manufacturers. Bring your medical records and any relevant lab work so the international provider has full context for your treatment.
Telemedicine peptide prescribers who operate across state lines or internationally have also emerged as a middle ground. Some of these providers connect US patients with international pharmacies that ship to the US. The legality of this arrangement is murky and varies by the specific medication and the states involved. Having clear legal guidance before going this route protects you from potential regulatory problems.
Where This Is Heading
The regulatory trend is clearly toward tighter control of the peptide market. More compounds will likely be restricted from compounding over the coming years. At the same time, pharmaceutical companies are pursuing FDA approval for some peptides (like semaglutide, which is already approved) and conducting clinical trials on others (like BPC-157, where trials have been registered though not yet completed).
The likely long-term outcome is a bifurcated market. FDA-approved peptides will be available through standard prescriptions but at pharmaceutical prices. Non-approved peptides will become harder to access through legal channels, pushing some of the market underground or overseas.
For consumers, this means several practical things. If a peptide you use is currently available through compounding, do not assume it will be available indefinitely. Stay informed about regulatory changes through reliable sources rather than forum speculation. Build a relationship with a prescribing physician who can navigate the evolving space and adjust your protocol as access changes.
Making Informed Decisions in an Uncertain Space
Dr. Tatem is bottom line is that peptide therapy occupies a space where the science is often ahead of the regulation, and the regulation is often influenced by factors beyond pure public health. Neither blanket acceptance nor blanket rejection of peptides is a rational position.
Evaluate each peptide individually based on the strength of its evidence, the quality of the source, and the guidance of a knowledgeable practitioner. Do not assume that a peptide is safe just because it is available, and do not assume it is dangerous just because the FDA has restricted it. The FDA is decisions reflect a mix of genuine safety concerns, political pressure, and pharmaceutical industry influence that requires a nuanced reading rather than blind trust.
Stay on the right side of the law. Using compounding pharmacies with valid prescriptions keeps you in a defensible legal position. Purchasing from research chemical suppliers for self-administration carries legal risk that increases as enforcement tightens.
Keep your physician in the loop. Even if you are more knowledgeable about peptides than your doctor (which is common in this space), having a licensed prescriber involved in your care provides a medical safety net and maintains legal access to compounded products that remain available.